In a new study, published in Arthritis Research & Therapy, a research team led by Soo-Kyung Cho, MD, sought to investigate the incidence of malignancy in early rheumatoid arthritis and found that the use of biologic disease-modifying anti-rheumatic drugs decreased the overall risk of developing malignancies, though it did not affect the risk of developing hematologic malignancies.